Its primary mechanisms are: Actin regulation critical for cell migration and tissue repair Anti-inflammatory signalling through the NF-B pathway19 Angiogenesis promoting new vessel formation in damaged tissue20 Cardioprotection demonstrating direct myocardial repair properties in animal models21 TB-500 Cardiovascular Long COVID: The Strongest Use Case Long COVID cardiovascular sequelae are well-documented: Myocarditis and pericarditis in a subset of patients POTS (postural orthostatic tachycardia syndrome) Reduced VO max and exercise intolerance Microclotting and endothelial damage TB-500's most compelling evidence base is cardiovascular
For patients with persistent symptoms, seeking care from a gastroenterologist is essential to assess and manage the condition properly
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
BPC-157 is supplied as a high-purity peptide with molecular formula C62H98N16O22 , molecular weight 1419.55 g/mol , and CAS number 137525-51-0
A., Jenner, T
